Therapeutics · Supplements and Botanicals

Benefits of α-lipoic acid in high-risk pregnancies (Review)

Petca A, Bot M, Maru N, Calo IG, Borislavschi A, Dumitrascu MC, Petca RC, Sandru F, Zvanca ME

Published November 2021 Experimental and Therapeutic Medicine, 22(5), 1232
DOI 10.3892/etm.2021.10666 PMID 34539828 PMC PMC8438679

RRM Academy Synopsis

Alpha-lipoic acid eased threatened miscarriage signs in small studies

A 2021 review of five small pregnancy studies reports that alpha-lipoic acid eased symptoms in threatened miscarriage and preterm labor risk. The supplement is an antioxidant. Women had early bleeding, contractions, or a shortening cervix.

Key Findings

  • Porcaro 2015, with alpha-lipoic acid added to progesterone versus progesterone alone: vaginal bleeding remission 89 vs. 71%, and pelvic pain improvement after 1 week 78 vs. 43%.
  • Porcaro 2015 reported a 50% resorption of the subchorionic hematoma in the first week and 90% resorption after 15 days with the combined treatment.
  • Costantino 2016 (62 women, 7-12 weeks): 80% hematoma resorption in alpha-lipoic acid patients at 20 days. The study groups receiving treatment did not differ significantly.
  • Parente 2014 gave alpha-lipoic acid with magnesium to 300 women at 14-34 weeks: 52% had no premature contractions and 28% had sporadic episodes needing no other tocolytic medication.
  • Grandi 2017 (40 women after a first preterm labor episode, 20 treated): monthly cervical shortening held at the expected 3 mm, and double that rate occurred on placebo.

Interpretation

The authors wrote a narrative review of five small clinical studies, with 16 to 300 women each. Several are called pilot or preliminary, and the review asks for larger groups. The results cover symptoms, hematoma resorption, contractions, and cervical change. Much of the mechanism comes from in vitro and animal work, and some researchers dispute antioxidant activity in the body because oral doses may not reach sufficient blood levels. The preeclampsia and fetal brain ideas are proposals, and the brain evidence cited comes from rodents.

RRM Context

Restorative reproductive medicine asks why a pregnancy is threatened. The review says miscarriage and preterm birth share a pathway of cytokine imbalance, which suits a cause-based question. In the Porcaro trial both groups also got progesterone, so progesterone support stays in the picture.

Abstract

α-Lipoic acid (ALA) is a natural molecule that is inconsistently synthesized by the human body and must be provided from exogenous sources, such as food and dietary supplements. Once absorbed, the oxidized form of ALA is transformed into its reduced form, dihydrolipoic acid (DHLA). ALA/DHLA exert direct and indirect antioxidant, anti-inflammatory and fine immunomodulatory effects. ALA/DHLA reduce the levels of pro-inflammatory cytokines (IL-1β, IL-6, IL-8 and IL-17), while increasing the secretion of anti-inflammatory cytokines (IL-10). They also inhibit cyclooxygenase 2, thereby decreasing the secretion of prostaglandin E2 and nitrogen oxide, and reducing the risk of miscarriage in the first trimester of pregnancy. In patients at risk of abortion, administration of ALA from the first trimester has shown efficacy by accelerating subchorionic hematoma resorption, with a significant decrease in the accompanying abdominal pain. ALA has been proven to be efficient in maintaining the length of the cervix and keeping it closed following one episode of premature labor. Preeclampsia is a dysfunction caused by abnormal placentation and an excessive maternal inflammatory response, leading to extreme hypoxia in the placental bed and exaggerated oxidative stress, with release of oxygen free radicals. Oxidative stress plays a key role in the development of preeclampsia and intrauterine growth restriction. The hypothesis of antioxidant supplementation may play an essential part in disease prevention and fetal neuroprotection.

Topics

Related research

Therapeutics › Supplements and Botanicals › Antioxidant Supplements · Pregnancy › Pregnancy Complications › Hypertensive Disorders · Birth and Delivery › Birth Outcomes › Maternal Morbidity
Aida Petca, Mihaela Bot, Nicoleta Maru, Ioana Gabriela Calo, Andreea Borislavschi, Mihai Cristian Dumitrascu, Razvan-Cosmin Petca, Florica Sandru, Mona Elena Zvanca
A Petca, M Bot, N Maru, I Calo, A Borislavschi, M Dumitrascu, R Petca, F Sandru, M Zvanca
PMID 34539828 34539828 DOI 10.3892/etm.2021.10666 10.3892/etm.2021.10666 Petca et al. 2021, Petca 2021